We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) and Eli Lilly and Company (LLY - Free Report) announced that their NGF inhibitor, tanezumab, met all co-primary endpoints in a phase III study evaluating it in patients with osteoarthritis (“OA”) pain.
Top-line data from the study evaluating the non-opioid candidate showed that treatment with tanezumab led to a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA – the three primary endpoints – compared to placebo at 16 weeks. The patients were administered two injections of tanezumab once every eight weeks. The safety data were consistent with earlier studies.
A few investors were skeptical about safety concerns related to the candidate. However, consistent results should alleviate some safety concerns.
In October 2013, the two companies signed an agreement for the joint development and commercialization of tanezumab across the world.
Tanezumab works by inhibiting nerve growth factor, which suppresses pain signal in the body. A potential approval to the candidate will provide a safer pain medication for patients in the United States where opioid abuse is widespread. Moreover, the currently approved drugs are underserving patients who continue to suffer from pain.
The candidate enjoys Fast Track designation in the United States for this indication, which is expected to expedite the review process. Osteoarthritis is a progressive disease, which impacts millions of people worldwide.
The companies are also evaluating the candidate in late-stage studies for chronic low back pain and cancer pain.
We remind investors that Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Teva Pharmaceutical Industries Limited (TEVA - Free Report) are also developing a NGF antibody, fasinumab for treating OA.
So far this year, shares of Pfizer and Lilly have risen 4% and 6.6%, respectively, against the industry’s decline of 0.7%.
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
Pfizer Inc. (PFE - Free Report) and Eli Lilly and Company (LLY - Free Report) announced that their NGF inhibitor, tanezumab, met all co-primary endpoints in a phase III study evaluating it in patients with osteoarthritis (“OA”) pain.
Top-line data from the study evaluating the non-opioid candidate showed that treatment with tanezumab led to a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA – the three primary endpoints – compared to placebo at 16 weeks. The patients were administered two injections of tanezumab once every eight weeks. The safety data were consistent with earlier studies.
A few investors were skeptical about safety concerns related to the candidate. However, consistent results should alleviate some safety concerns.
In October 2013, the two companies signed an agreement for the joint development and commercialization of tanezumab across the world.
Tanezumab works by inhibiting nerve growth factor, which suppresses pain signal in the body. A potential approval to the candidate will provide a safer pain medication for patients in the United States where opioid abuse is widespread. Moreover, the currently approved drugs are underserving patients who continue to suffer from pain.
The candidate enjoys Fast Track designation in the United States for this indication, which is expected to expedite the review process. Osteoarthritis is a progressive disease, which impacts millions of people worldwide.
The companies are also evaluating the candidate in late-stage studies for chronic low back pain and cancer pain.
We remind investors that Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Teva Pharmaceutical Industries Limited (TEVA - Free Report) are also developing a NGF antibody, fasinumab for treating OA.
So far this year, shares of Pfizer and Lilly have risen 4% and 6.6%, respectively, against the industry’s decline of 0.7%.
Zacks Rank
Pfizer and Lilly currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>